Kevin joined atai Life Sciences in 2021. He has over 20 years of clinical experience, with 13 years in the industry and a decade in clinical and academic settings. Prior to joining atai, he was Head of Early Clinical Development at Jazz Pharmaceuticals where he was responsible for the design and execution of rapid decision-making clinical trials across the early neuroscience pipeline.

Prior to joining Jazz, Kevin spent a number of years at Covance, a large clinical research organization, as senior director in the neuroscience therapy area. He moved to clinical pharmacology to become Head of Clinical Science in 2017, providing medical and scientific support for phase 1 studies across all therapy areas.

Before joining the industry, Kevin held a faculty appointment at the Behavioral and Clinical Neuroscience Institute at the University of Cambridge and has published widely on the cognition and brain imaging in mental health. He began his industry career at P1vital, developing imaging and cognitive biomarkers to enhance decision-making for early-phase psychiatry trials.

Dr. Craig holds a medical degree from the University of Witwatersrand, South Africa, a master’s degree from the University of Cambridge, and specialist accreditation in addiction and adult psychiatry.